MX2023005612A - Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. - Google Patents

Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.

Info

Publication number
MX2023005612A
MX2023005612A MX2023005612A MX2023005612A MX2023005612A MX 2023005612 A MX2023005612 A MX 2023005612A MX 2023005612 A MX2023005612 A MX 2023005612A MX 2023005612 A MX2023005612 A MX 2023005612A MX 2023005612 A MX2023005612 A MX 2023005612A
Authority
MX
Mexico
Prior art keywords
psma
modified form
cells
specific membrane
engineered cells
Prior art date
Application number
MX2023005612A
Other languages
English (en)
Inventor
Hyam I Levitsky
Martin G Pomper
David Jeffrey Huss
Il Minn
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2023005612A publication Critical patent/MX2023005612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Se proporcionan células, tales como células modificadas genéticamente, que expresan un antígeno de membrana específico de próstata (PSMA) o una forma modificada del mismo. En algunas modalidades, la célula contiene además un receptor recombinante genéticamente modificado, tal como un receptor de antígeno quimérico, que se une específicamente a un antígeno. La presente descripción también proporciona métodos para detectar, identificar, seleccionar o dirigirse a células que expresan PSMA, tal como en relación con la administración de tales células a sujetos, incluyendo métodos de terapia celular adoptiva, o en relación con métodos de fabricación de células modificadas.
MX2023005612A 2017-04-07 2019-10-04 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. MX2023005612A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762483313P 2017-04-07 2017-04-07
US201762552354P 2017-08-30 2017-08-30
US201762555635P 2017-09-07 2017-09-07
US201762582913P 2017-11-07 2017-11-07
US201862619724P 2018-01-19 2018-01-19

Publications (1)

Publication Number Publication Date
MX2023005612A true MX2023005612A (es) 2023-05-29

Family

ID=62152629

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012017A MX2019012017A (es) 2017-04-07 2018-04-07 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
MX2023005612A MX2023005612A (es) 2017-04-07 2019-10-04 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019012017A MX2019012017A (es) 2017-04-07 2018-04-07 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.

Country Status (8)

Country Link
US (1) US20230190796A1 (es)
EP (1) EP3607319A1 (es)
JP (1) JP7284707B2 (es)
CN (1) CN110730908A (es)
AU (1) AU2018250336A1 (es)
CA (1) CA3056261A1 (es)
MX (2) MX2019012017A (es)
WO (1) WO2018187791A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
WO2021098834A1 (zh) * 2019-11-22 2021-05-27 上海一宸医药科技有限公司 Psma抗体及其应用
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
JP2023514333A (ja) * 2020-02-18 2023-04-05 エンドサイト・インコーポレイテッド Ｐｓｍａ発現がんを処置する方法
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112197879B (zh) * 2020-09-14 2021-10-12 中国科学院西安光学精密机械研究所 一种高时间分辨单光子探测方法及单光子探测系统
US20230414762A1 (en) * 2020-11-17 2023-12-28 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
CN117441010A (zh) 2021-04-07 2024-01-23 世纪治疗股份有限公司 从诱导多能干细胞产生α-βT细胞的组合物和方法
JP2024519515A (ja) 2021-04-07 2024-05-15 センチュリー セラピューティクス，インコーポレイテッド 人工多能性幹細胞からガンマ－デルタｔ細胞を生成するための組成物および方法
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
ES2195036T3 (es) 1995-12-22 2003-12-01 Bristol Myers Squibb Co Conectores de hidrazona ramificados.
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
DE69938293T2 (de) 1998-03-27 2009-03-12 Bruce J. Beverly Hills Bryan Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
ID28040A (id) 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1520588B1 (en) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System Uses of antibodies to aminophospholipids for cancer treatment
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
ATE282205T1 (de) 2000-07-24 2004-11-15 Health Research Inc Verfahren zur detektion von prostata-spezifischem membran-antigen in serum
WO2002077029A2 (en) 2000-11-07 2002-10-03 City Of Hope Cd19-specific redirected immune cells
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US20020147312A1 (en) 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002096460A1 (en) 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
WO2004063701A2 (en) 2003-01-10 2004-07-29 Millennium Pharmaceuticals, Inc. Methods of diagnosing and treating cancer
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
EP1610818A4 (en) 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP1841467A4 (en) 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
WO2006078892A2 (en) 2005-01-21 2006-07-27 The Regents Of The University Of California Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
WO2006105328A1 (en) 2005-03-31 2006-10-05 C.T. Airtech, Llc Ceiling air deflector insert and method of assembly
JP2008535865A (ja) 2005-04-08 2008-09-04 サイトジェン コーポレーション 抗ｐｓｍａコンジュゲート抗体
PL1912677T3 (pl) 2005-06-20 2014-03-31 Psma Dev Company L L C Koniugaty przeciwciało PSMA-lek
EP1909832A4 (en) 2005-06-29 2010-01-13 Univ Miami ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
WO2007059190A2 (en) 2005-11-14 2007-05-24 Psma Development Company, Llc. Compositions of and methods of using stabilized psma dimers
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US20100178299A1 (en) 2007-02-13 2010-07-15 Northeastern University Methods and compositions for improving immune responses
EP2141997B1 (en) 2007-03-30 2012-10-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
US8229090B2 (en) 2007-04-17 2012-07-24 Verizon Patent And Licensing Inc. Voice portal communications
CA2926573C (en) 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
AU2015203742B2 (en) 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US8747290B2 (en) 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
CN113563262A (zh) 2008-08-01 2021-10-29 约翰.霍普金斯大学 Psma-结合剂及其用途
EP2326350B1 (en) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
US8883500B2 (en) 2008-12-05 2014-11-11 Northeastern University Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
WO2010135431A2 (en) 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
EP4049674A1 (en) * 2009-11-03 2022-08-31 City of Hope Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection
MX354143B (es) 2009-12-02 2018-02-14 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
US20120067162A1 (en) 2010-09-17 2012-03-22 Steven Kollmann Steering Wheel Armature Weight
EP3305798A1 (en) 2010-12-09 2018-04-11 The Trustees of The University of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2791716T3 (es) 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
US9079952B2 (en) 2011-01-10 2015-07-14 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US20140060461A1 (en) 2011-03-31 2014-03-06 General Electric Company Power generation system utilizing a fuel cell integrated with a combustion engine
CN106632677B (zh) 2011-04-01 2021-10-26 纪念斯隆-凯特琳癌症中心 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
AU2012245260B2 (en) * 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
WO2013109759A1 (en) 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
WO2013116516A1 (en) 2012-02-03 2013-08-08 Wayne State University Fourier-transform interferometer with staircase reflective element
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CA2865282A1 (en) 2012-02-24 2013-08-29 Cornell University Elevated psma identifies lethal prostate cancers
US20130315830A1 (en) 2012-02-28 2013-11-28 Cornell University PSMA as a BioMarker for Androgen Activity in Prostate Cancer
US9200260B2 (en) 2012-03-15 2015-12-01 New England Biolabs, Inc. Compositions and methods for the transfer of a hexosamine to a modified nucleotide in a nucleic acid
CA2872471C (en) 2012-05-03 2022-11-22 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
DE102012009836A1 (de) 2012-05-16 2013-11-21 Carl Zeiss Microscopy Gmbh Lichtmikroskop und Verfahren zur Bildaufnahme mit einem Lichtmikroskop
US9766244B2 (en) 2012-07-02 2017-09-19 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
RU2019126655A (ru) 2012-08-20 2019-11-12 Фред Хатчинсон Кансэр Рисёч Сентер Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
CN112430580A (zh) 2012-10-02 2021-03-02 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
US20140099257A1 (en) 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
LT2906253T (lt) 2012-10-12 2018-10-10 Adc Therapeutics Sa Pirolobenzodiazepino-anti-psma antikūno konjugatas
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
US9605217B2 (en) 2013-06-20 2017-03-28 Exxonmobil Research And Engineering Company Sequential slurry hydroconversion of heavy oils
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
BR112016014156A8 (pt) 2013-12-20 2023-04-11 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e receptores das mesmas
MY177390A (en) 2014-01-10 2020-09-14 Byondis Bv Method for purifying cys-linked antibody-drug conjugates
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
US10743909B2 (en) 2014-04-03 2020-08-18 Corbin Clinical Resources, Llc Transperineal prostate biopsy device, systems, and methods of use
CA2984484C (en) 2014-05-02 2024-01-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
ES2895623T3 (es) 2014-05-22 2022-02-22 Byondis Bv Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes
CN107075483A (zh) * 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 用于过继细胞治疗的工程改造的细胞
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
MA41046A (fr) 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
WO2016130819A2 (en) 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
KR20180012740A (ko) 2015-03-10 2018-02-06 소렌토 쎄라퓨틱스, 인코포레이티드 Psma에 결합하는 항체 치료제
EP3307282A4 (en) 2015-06-12 2019-05-01 Immunomedics, Inc. TREATMENT OF DISEASES WITH CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (T-CAR) OR NK (CAR-NK) CELL EXPRESSION CONSTRUCTIONS CAR CONSTRUCTIONS
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN108697096B (zh) * 2016-09-02 2022-05-03 康奈尔大学 对icam-1特异性的i结构域嵌合抗原受体

Also Published As

Publication number Publication date
US20230190796A1 (en) 2023-06-22
MX2019012017A (es) 2020-02-12
EP3607319A1 (en) 2020-02-12
WO2018187791A1 (en) 2018-10-11
AU2018250336A1 (en) 2019-09-26
CA3056261A1 (en) 2018-10-11
JP2020516248A (ja) 2020-06-11
JP7284707B2 (ja) 2023-05-31
CN110730908A (zh) 2020-01-24

Similar Documents

Publication Publication Date Title
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
NZ725201A (en) Improved methods for manufacturing adoptive cell therapies
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
CY1121979T1 (el) Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις
EP3656387A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
NZ765695A (en) Immune cell organoid co-cultures
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2022015399A (es) Conjugados de superficie celular y composiciones y metodos celulares relacionados.
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
NZ758715A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2018001568A (es) Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
WO2018102787A9 (en) Methods for determining car-t cells dosing
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX2019006285A (es) Metodos para modulacion de celulas cart-t.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2021001771A (es) Polipéptidos del receptor de antígeno quimérico en combinación con moléculas del metabolismo trans que modulan el ciclo de krebs y usos terapéuticos de los mismos.
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2021012030A (es) Instrumentacion automatizada para la produccion de bibliotecas de peptidos de receptores de celulas t.